Page 29 - Tryp Therapeutics News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Psychedelics Could be Your Next Multi-Billion-Dollar Opportunity It may only be a matter of time before mind-altering drugs make their way into Big Pharma treatments for mental health issues, such as depression, anxiety, obsessive compulsive disorder, trauma, and addiction. If that happens, the industry could be worth well over $100 billion, as noted by analyst at Eight Capital, benefiting companies such as Silo Wellness (CSE:SINO), Compass Pathways Inc. (NASDAQ:CMPS), HAVN Life Sciences Inc. (CSE:HAVN), and Tryp Therapeutics Inc. (CSE:TRYP). Helping even more, a bill to decriminalize psychedelics in California is moving forward. In fact, according to Benzinga, “Introduced in February by Sen. Scott Wiener, SB 519 would remove penalties for the possession, personal use and social sharing of certain natural and synthetic psychoactive drugs including psilocybin, psilocyn, DMT, ibogaine, mescaline, LSD, ketamine and MDMA.”

United statesDouglas gordonDwayne isaacsScott wienerMaurice moe colsonDouglask gordonAugustine ventures incClearing corporationDelta uranium incUniversity in ontarioCompass pathways incTrademark officeField trip health ltdTryp therapeutics incCanadian securities exchangeForsys metals corporation